1️⃣ Lilly just paid peak private-market pricing for in vivo CAR-T
Lilly agreed on April 20 to buy Kelonia for up to $7B, including $3.25B upfront, to get its Phase 1 KLN-1010 multiple myeloma program and in vivo gene placement platform.
💡 Why it matters
This is not payment for mature data. Lilly is paying for a shot at removing the manufacturing and preconditioning friction that still keeps CAR-T smaller than it should be.
☕ Coffee talk
Four patients and no lymphodepletion were enough for $3.25B upfront. How high is the bar for every ex vivo CAR-T platform now?
2️⃣ Ray pulled crossover money into ocular gene therapy
Ray Therapeutics closed an upsized $125M Series B on April 21, with Janus Henderson leading and Franklin Templeton, Adage, Invus and Marshall Wace joining after RTx-015 picked up RMAT status this month.
💡 Why it matters
This is what late-stage private confidence looks like. Optogenetics just moved closer to a financeable category, not a clever science project waiting for patience.
☕ Coffee talk
Janus, Franklin and Novo all wrote checks here. How many eye-gene-therapy stories can still claim they are pre-consensus?
3️⃣ Nektar finally has a cleaner first-line alopecia angle
Nektar said on April 20 that 52-week Phase 2b REZOLVE-AA data pushed SALT<=20 responses to 25.8% and 27.6% versus 6.7% on placebo, with no extension dropouts from adverse events.
💡 Why it matters
The efficacy matters, but the strategic angle is safety. A biologic with cleaner prescribing baggage than JAKs could widen the treated pool and give Treg immunology a more credible commercial path.
☕ Coffee talk
Alopecia is the headline, but the safety angle is doing the real work here. Does that open more room in Treg immunology than the market is pricing?